BB Biotech
CRSP icon

BB Biotech’s CRISPR Therapeutics CRSP Stock Holding History

BB Biotech’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$29M Buy
+810,462
New +$28M 0.73% 27

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Waddell & Reed Financial
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BB Biotech's CRSP Position: Q1 2019 in Review

BB Biotech opened a new position in CRISPR Therapeutics (CRSP) in Q1 2019: 810,462 shares worth $29M. The stake represents 0.73% of the portfolio and ranks #27 among its holdings.

170 funds tracked by Wall St. Rank hold CRSP as of Q1 2019.

  • BB Biotech held 810,462 shares of CRISPR Therapeutics worth $29M as of Q1 2019.
  • CRISPR Therapeutics was a new BB Biotech position in Q1 2019.
  • CRISPR Therapeutics made up 0.73% of BB Biotech's portfolio in Q1 2019, its #27 holding.
  • 170 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.